新抗炎症薬4-Ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone(M73101)の代謝(第3報)ラットにおける生体内動態およびイヌにおける腎からの排泄
スポンサーリンク
概要
- 論文の詳細を見る
The fate of ^3H-labeled 4-ethoxy-2-methyl-5-morpholino-3 (2H)-pyridazinone (^3H-M73101) in rats and the excretion of M73101 from dog kidney were studied. When ^3H-M73101 was given orally to rats, it was rapidly absorbed from the gastro-intestinal tract and widely distributed throughout the tissues. Particularly, higher radioactivity was detected in the stomach, kidney and liver. Plasma concentration reached maximum at 1 hr after administration and maintained that level for 3 hr ; thereafter, radioactivity rapidly decreased. The time courses of radioactivity in many tissues were similar to those in plasma. Autoradiographic results were in good accord with those described above. Radioactivity was found also in the inflammed site and carboxymethyl cellulose (CMC) pouch of rats at 1 hr after administration. At 6 hr, radioactivity in the skin and muscle in contact with the CMC pouch was higher than that at normal sites. Excretions into the urine and feces within 24 hr were 68.6% and 18.9% of the dose, respectively. About 10% of the dose was excreted into the bile within 24 hr, in which parent compound and 6 metabolites were detected. When the excreted bile was administered into the duodenum, 23% of the dose was excreted again into the bile. From the result of the experiment using a renal clearance method in dogs, it was found that more than 95% of M73101 was reabsorbed from the renal tubule by passive transport. The relationship between the fate and the pharmacological activity of M73101 is also discussed.
- 社団法人日本薬学会の論文
- 1979-11-25
著者
-
林 敏廣
ヘキスト・マリオン・ルセル(株)輸液研究部
-
網野 光人
ヘキスト・マリオン・ルセル(株)輸液研究部
-
林 敏廣
森下製薬株式会社薬理研究所
-
網野 光人
森下製薬株式会社薬理研究所
-
山口 東
森下製薬株式会社薬理研究所
-
松尾 俊康
森下製薬株式会社薬理研究所
-
山口 東
Research Laboratories, Morishita Pharmaceutical Co., Ltd.
-
山口 東
Research Laboratories Morishita Pharmaceutical Co. Ltd.
関連論文
- 潰瘍性大腸炎治療薬5-[4-(2-Carboxyethylcarbamoyle)-phenylazo] Salicylic Acid Disodium Salt Dihydrate (BX661A) の体内動態(第4報) : ラットに反復経口投与したときの血漿中濃度推移,分布,代謝および排泄
- 潰瘍性大腸炎治療薬5-[4-(2-Carboxyethylcarbamoyle) -phenylazo] Salicylic Acid Disodium Salt Dihydrate (BX661A) の体内動態(第3報) : ラットに単回投与したときの分布および排泄
- 潰瘍性大腸炎治療薬5-[4-(2-Carboxyethylcarbamoyle)-phenylazo] Salicylic Acid Disodium Salt Dihydrate (BX661A)の体内動態(第2報) : DSS誘発潰瘍性大腸炎モデルラットに単回投与したときの血漿中濃度推移および消化管内挙動
- 潰瘍性大腸炎治療薬5-[4-(2-Carboxyethylcarbamoyle)-phenylazo] Salicylic Acid Disodium Salt Dihydrate(BX661A)の体内動態(第1報) : ラットに単回投与したときの血漿中濃度推移
- デキストラン硫酸誘発潰瘍性大腸炎モデルラットにおける大腸遊離型 5-aminosalicylic acid 製剤 "BX661A" の体内動態
- 潰瘍性大腸炎の治療を目的とした大腸遊離型 5-aminosalicylic acid (5ASA)製剤 "BX661A" の体内動態 (消化管内動態について)
- 新抗炎症薬4-Ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone(M73101)の代謝(第4報)血中濃度および消化管吸収
- 新抗炎症薬4-Ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone(M73101)の代謝(第3報)ラットにおける生体内動態およびイヌにおける腎からの排泄
- 1,2-ナフトキノン誘導体の合成と止血作用
- ピリダジノン誘導体の研究(第9報)2,4,5-トリ置換-3(2H)-ピリダジノン類の合成と止血作用
- Studies on New Antiulcer Agents. I. Synthesis and Antisecretory Activity of Pyridazine Derivatives
- 市販生体標準試料を用いたマイクロウエーブ灰化法の基礎検討
- ビリダジノン誘導体の研究(第10報)4,5-Dihydro-2,6-disubstituted-3(2H)-pyridazinone誘導体の合成と利尿および降圧作用
- アミノ酸輸液の注入速度と急性毒性
- Effects of 4-Ethoxy-2-methy1-5-morpholino-3 (2H) -pyridazinone (M 73101) on Healthy Man. II. Blood Concentration and Urinary Excretion